1 résultat
Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
Auteurs / Authors
V. Gounant, L. Greillier, C. Mascaux, F. Pinquie, D. Carmier, L. Moreau, B. Roch, D. Debieuvre, X. Dhalluin, E. Giroux-leprieur, E. Berton, A. Rabeau, J. Raimbourg, A. Dixmier, C. Naltet, A. Khalil, L. Ezzeddine, A. Langlais, F. Morin, M. Duruisseaux
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT